Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects With Genotype 2 or 3 Chronic HCV Infection.

NCT01962441 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01962441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01962441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects With Genotype 2 or 3 Chronic HCV Infection.
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
September 24, 2013
Completion date
July 7, 2016
Enrollment
601 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c